View Item 

Show simple item record

Estimation of CYP 2 D 6*10 genotypes on citalopram disposition in C hinese subjects by population pharmacokinetic assay

dc.contributor.authorChen, B.en_US
dc.contributor.authorXu, Y.en_US
dc.contributor.authorJiang, T.en_US
dc.contributor.authorFeng, R.en_US
dc.contributor.authorSun, J.en_US
dc.contributor.authorZhang, W.en_US
dc.contributor.authorYang, W.en_US
dc.contributor.authorLi, J.en_US
dc.contributor.authorAdeniyi, O.en_US
dc.contributor.authorChen, H.en_US
dc.date.accessioned2013-11-01T19:00:47Z
dc.date.available2015-01-05T13:54:44Zen_US
dc.date.issued2013-12en_US
dc.identifier.citationChen, B.; Xu, Y.; Jiang, T.; Feng, R.; Sun, J.; Zhang, W.; Yang, W.; Li, J.; Adeniyi, O.; Chen, H. (2013). "Estimation of CYP 2 D 6*10 genotypes on citalopram disposition in C hinese subjects by population pharmacokinetic assay." Journal of Clinical Pharmacy and Therapeutics 38(6): 504-511.en_US
dc.identifier.issn0269-4727en_US
dc.identifier.issn1365-2710en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/100259
dc.publisherWiley Periodicals, Inc.en_US
dc.subject.otherCitalopramen_US
dc.subject.otherGenotypeen_US
dc.subject.otherCYP 2 D 6en_US
dc.subject.otherCYP 2 C 19en_US
dc.subject.otherPopulation Pharmacokineticen_US
dc.subject.otherNon‐Compartmenten_US
dc.subject.otherBioequivalenceen_US
dc.titleEstimation of CYP 2 D 6*10 genotypes on citalopram disposition in C hinese subjects by population pharmacokinetic assayen_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelPharmacy and Pharmacologyen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/100259/1/jcpt12029.pdf
dc.identifier.doi10.1111/jcpt.12029en_US
dc.identifier.sourceJournal of Clinical Pharmacy and Therapeuticsen_US
dc.identifier.citedreferenceKobayashi K, Chiba K, Yagi T et al. Identification of cytochrome P450 isoforms involved in citalopram N‐demethylation by human liver microsomes. J Pharmacol Exp Ther, 1997; 280: 927 – 933.en_US
dc.identifier.citedreferenceRochat B, Amey M, Gillet M, Meyer UA, Baumann P. Identification of three cytochrome P450 isozymes involved in N‐demethylation of citalopram enantiomers in human liver microsomes. Pharmacogenetics, 1997; 7: 1 – 10.en_US
dc.identifier.citedreferencede Morais SM, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, Goldstein JA. The major genetic defect responsible for the polymorphism of S‐mephenytoin metabolism in humans. J Biol Chem, 1994; 269: 15419 – 15422.en_US
dc.identifier.citedreferenceOlesen OV, Linnet K. Studies on the stereoselective metabolism of citalopram by human liver microsomes and cDNA‐expressed cytochrome P450 enzymes. Pharmacology, 1999; 59: 298 – 309.en_US
dc.identifier.citedreferenceBaumann P, Rochat B. Comparative pharmacokinetics of selective serotonin reuptake inhibitors: a look behind the mirror. Int Clin Psychopharmacol, 1995; 10 ( Suppl 1 ): 15 – 21.en_US
dc.identifier.citedreferenceJoffe P, Larsen FS, Pedersen V, Ring‐Larsen H, Aaes‐Jørgensen T, Sidhu J. Single‐dose pharmacokinetics of citalopram in patients with moderate renal insufficiency or hepatic cirrhosis compared with healthy subjects. Eur J Clin Pharmacol, 1998; 54: 237 – 242.en_US
dc.identifier.citedreferenceLeinonen E, Lepola U, Koponen H, Kinnunen I. The effect of age and concomitant treatment with other psychoactive drugs on serum concentrations of citalopram measured with a nonenantioselective method. Ther Drug Monit, 1996; 18: 111 – 117.en_US
dc.identifier.citedreferenceFredricson Overø K. Kinetics of citalopram in man: plasma levels in patients. Prog Neuropsychopharmacol Biol Psychiatry, 1982; 6: 311 – 318.en_US
dc.identifier.citedreferenceSindrup SH, Brøsen K, Hansen MG, Aaes‐Jørgensen T, Overø KF, Gram LF. Pharmacokinetics of citalopram in relation to the sparteine and the mephenytoin oxidation polymorphisms. Ther Drug Monit, 1993; 15: 11 – 17.en_US
dc.identifier.citedreferenceMaier GA, Lockwood GF, Oppermann JA, Wei G, Bauer P, Fedler‐Kelly J, Grasela T. Characterization of the highly variable bioavailability of tiludronate in normal volunteers using population pharmacokinetic methodologies. Eur J Drug Metab Pharmacokinet, 1999; 24: 249 – 254.en_US
dc.identifier.citedreferenceFradette C, Lavigne J, Waters D, Ducharme MP. The utility of the population approach applied to bioequivalence in patients. Ther Drug Monit, 2005; 27: 592 – 600.en_US
dc.identifier.citedreferenceHerrlin K, Yasui‐Furukori N, Tybring G, Widén J, Gustafsson LL, Bertilsson L. Metabolism of citalopram enantiomers in CYP2C19/CYP2D6 phenotyped panels of healthy Swedes. Br J Clin Pharmacol, 2003; 56: 415 – 421.en_US
dc.identifier.citedreferenceYu BN, Chen GL, He N, Ouyang DS, Chen XP, Liu ZQ, Zhou HH. Pharmacokinetics of citalopram in relation to genetic polymorphism of CYP2C19. Drug Metab Dispos, 2003; 31: 1255 – 1259.en_US
dc.identifier.citedreferenceSpigset O, Hägg S, Stegmayr B, Dahlqvist R. Citalopram pharmacokinetics in patients with chronic renal failure and the effect of haemodialysis. Eur J Clin Pharmacol, 2000; 56: 699 – 703.en_US
dc.identifier.citedreferenceFriberg LE, Isbister GK, Hackett LP, Duffull SB. The population pharmacokinetics of citalopram after deliberate self‐poisoning: a Bayesian approach. J Pharmacokinet Pharmacodyn, 2005; 32: 571 – 605.en_US
dc.identifier.citedreferenceBies RR, Feng Y, Lotrich FE, Kirshner MA, Roose S, Kupfer DJ, Pollock BG. Utility of sparse concentration sampling for citalopram in elderly clinical trial subjects. J Clin Pharmacol, 2004; 44: 1352 – 1359.en_US
dc.identifier.citedreferenceKragh‐Sørensen P, Overø KF, Petersen OL, Jensen K, Parnas W. The kinetics of citalopram: single and multiple dose studies in man. Acta Pharmacol Toxicol (Copenh), 1981; 48: 53 – 60.en_US
dc.identifier.citedreferencePentikis HS, Henderson JD, Tran NL, Ludden TM. Bioequivalence: individual and population compartmental modeling compared to the noncompartmental approach. Pharm Res, 1996; 13: 1116 – 1121.en_US
dc.identifier.citedreferenceJiang T, Rong Z, Peng L et al. Simultaneous determination of citalopram and its metabolite in human plasma by LC‐MS/MS applied to pharmacokinetic study. J Chromatogr B Analyt Technol Biomed Life Sci, 2010; 878: 615 – 619.en_US
dc.identifier.citedreferenceCai WM, Chen B, Zhang WX. Frequency of CYP2D6 *10 and *14 alleles and their influence on the metabolic activity of CYP2D6 in a healthy Chinese population. Clin Pharmacol Ther, 2007; 81: 95 – 98.en_US
dc.identifier.citedreferenceLee EJ, Jeyaseelan K. Frequency of human CYP2D6 mutant alleles in a normal Chinese population. Br J Clin Pharmacol, 1994; 37: 605 – 607.en_US
dc.identifier.citedreferenceGarcia‐Barcelo M, Chow LY, Chiu HF, Wing YK, Lee DT, Lam KL, Waye MM. Genetic analysis of the CYP2D6 locus in a Hong Kong Chinese population. Clin Chem, 2000; 46: 18 – 23.en_US
dc.identifier.citedreferenceHsieh KP, Lin YY, Cheng CL, Lai ML, Lin MS, Siest JP, Huang JD. Novel mutations of CYP3A4 in Chinese. Drug Metab Dispos, 2001; 29: 268 – 273.en_US
dc.identifier.citedreferenceDai D, Tang J, Rose R, Hodgson E, Bienstock RJ, Mohrenweiser HW, Goldstein JA. Identification of variants of CYP3A4 and characterization of their abilities to metabolize testosterone and chlorpyrifos. Biochem Pharmacol, 1992; 43: 2201 – 2208.en_US
dc.identifier.citedreferenceYin OQ, Wing YK, Cheung Y, Wang ZJ, Lam SL, Chiu HF, Chow MS. Phenotype‐genotype relationship and clinical effects of citalopram in Chinese patients. J Clin Psychopharmacol, 2006; 26: 367 – 372.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
jcpt12029.pdf
Size:
686.9KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.